Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

David Wyles

Concepts (239)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antiviral Agents
58
2025
712
11.380
 Why?
Hepatitis C, Chronic
31
2025
153
8.720
 Why?
Hepacivirus
46
2024
235
7.810
 Why?
Hepatitis C
27
2025
238
7.600
 Why?
Benzimidazoles
16
2020
162
4.350
 Why?
Drug Resistance, Viral
17
2018
110
3.260
 Why?
HIV Infections
28
2022
2721
3.120
 Why?
Coinfection
15
2020
131
3.110
 Why?
Ribavirin
15
2020
91
2.390
 Why?
Sofosbuvir
16
2022
58
2.330
 Why?
Quinoxalines
7
2019
64
2.310
 Why?
Sulfonamides
13
2020
495
2.290
 Why?
Fluorenes
7
2020
40
2.280
 Why?
Liver Cirrhosis
8
2020
279
2.230
 Why?
Viral Nonstructural Proteins
9
2018
58
1.990
 Why?
Drug Therapy, Combination
26
2020
1040
1.860
 Why?
Uridine Monophosphate
5
2016
15
1.720
 Why?
Carbamates
9
2020
46
1.490
 Why?
Anti-Retroviral Agents
5
2019
231
1.460
 Why?
Protease Inhibitors
10
2020
106
1.410
 Why?
Hepatitis B, Chronic
3
2019
18
1.370
 Why?
Proline
11
2020
76
1.290
 Why?
Pyrrolidines
9
2019
67
1.240
 Why?
Congresses as Topic
3
2021
216
1.200
 Why?
Hepatitis, Viral, Human
3
2021
25
1.170
 Why?
Genotype
19
2022
1835
1.010
 Why?
Cyclopropanes
11
2020
89
0.990
 Why?
Drug Users
2
2024
41
0.990
 Why?
Sustained Virologic Response
10
2020
37
0.940
 Why?
Lactams, Macrocyclic
10
2020
49
0.920
 Why?
Heterocyclic Compounds, 4 or More Rings
3
2017
19
0.820
 Why?
HIV-1
8
2020
837
0.800
 Why?
Virus Replication
7
2012
450
0.760
 Why?
Disease Eradication
1
2020
4
0.710
 Why?
Organophosphonates
4
2011
92
0.690
 Why?
Homosexuality, Male
2
2021
176
0.690
 Why?
Anti-HIV Agents
6
2020
754
0.670
 Why?
Humans
75
2025
129248
0.660
 Why?
Valine
7
2020
81
0.650
 Why?
Nucleic Acid Synthesis Inhibitors
2
2015
16
0.570
 Why?
Imidazoles
2
2015
234
0.550
 Why?
Ritonavir
6
2020
73
0.550
 Why?
Darunavir
1
2017
18
0.540
 Why?
Treatment Failure
5
2019
339
0.540
 Why?
Aminoisobutyric Acids
5
2019
7
0.530
 Why?
Uracil
5
2020
30
0.510
 Why?
Treatment Outcome
18
2023
10199
0.510
 Why?
Antiretroviral Therapy, Highly Active
3
2015
267
0.500
 Why?
Leucine
5
2019
108
0.500
 Why?
Anilides
5
2020
72
0.500
 Why?
Middle Aged
30
2025
31087
0.500
 Why?
Education, Medical, Continuing
1
2016
122
0.480
 Why?
Biomedical Research
1
2021
637
0.470
 Why?
Male
39
2025
63501
0.470
 Why?
Adenine
4
2020
256
0.450
 Why?
RNA, Viral
7
2015
619
0.450
 Why?
Oligopeptides
2
2013
258
0.440
 Why?
Viral Load
7
2020
448
0.440
 Why?
Pyridazines
1
2014
54
0.440
 Why?
2-Naphthylamine
5
2020
7
0.430
 Why?
Macrocyclic Compounds
3
2019
9
0.420
 Why?
Adult
29
2025
35495
0.420
 Why?
Female
37
2025
68543
0.420
 Why?
Purines
1
2014
172
0.410
 Why?
Quinolines
1
2014
156
0.410
 Why?
Replicon
3
2009
14
0.400
 Why?
Liver
1
2021
1839
0.400
 Why?
Disease Management
1
2016
588
0.390
 Why?
Scavenger Receptors, Class B
1
2012
11
0.390
 Why?
Aged
17
2024
22032
0.370
 Why?
Retreatment
2
2021
70
0.340
 Why?
Drug Synergism
3
2008
370
0.330
 Why?
Acquired Immunodeficiency Syndrome
2
2020
227
0.300
 Why?
Dideoxynucleosides
2
2005
20
0.300
 Why?
Liver Diseases
2
2016
290
0.300
 Why?
Interferon-alpha
4
2013
194
0.280
 Why?
Cytokines
1
2015
2013
0.280
 Why?
Amino Acid Substitution
2
2018
282
0.270
 Why?
Global Health
2
2020
327
0.260
 Why?
Cytosine
2
2009
46
0.260
 Why?
Hepatitis B virus
2
2019
35
0.240
 Why?
Mass Screening
3
2023
1149
0.230
 Why?
HIV
2
2019
227
0.230
 Why?
Hepatitis
1
2004
47
0.230
 Why?
Herpes Simplex
1
2005
92
0.230
 Why?
Alanine
2
2021
142
0.220
 Why?
Prevalence
3
2019
2554
0.210
 Why?
Interferons
2
2015
193
0.200
 Why?
Young Adult
10
2019
12388
0.200
 Why?
Hospitals
2
2024
630
0.200
 Why?
Mutation, Missense
3
2014
317
0.190
 Why?
Interferon beta-1a
1
2021
12
0.190
 Why?
Hepatitis A
1
2021
25
0.180
 Why?
Adenosine Monophosphate
1
2021
63
0.180
 Why?
Tenofovir
2
2020
231
0.180
 Why?
Hepatitis B
1
2021
63
0.170
 Why?
World Health Organization
1
2020
110
0.170
 Why?
Disease Progression
2
2019
2630
0.170
 Why?
Data Interpretation, Statistical
2
2018
336
0.160
 Why?
Polyethylene Glycols
2
2015
587
0.160
 Why?
United States
10
2025
13828
0.160
 Why?
Ribosomes
2
2010
164
0.150
 Why?
Esters
2
2009
73
0.150
 Why?
CD4 Lymphocyte Count
2
2017
266
0.150
 Why?
Immunologic Factors
1
2020
230
0.150
 Why?
Nucleic Acid Conformation
4
2014
706
0.140
 Why?
Hospitalization
2
2024
2052
0.140
 Why?
Alanine Transaminase
1
2018
153
0.140
 Why?
DNA, Viral
1
2019
349
0.140
 Why?
Genes, Viral
1
2016
82
0.130
 Why?
DNA Mutational Analysis
1
2018
385
0.130
 Why?
Mutation
2
2018
3710
0.130
 Why?
High-Throughput Nucleotide Sequencing
2
2016
485
0.130
 Why?
Molecular Structure
2
2008
478
0.130
 Why?
Patient Compliance
1
2020
563
0.130
 Why?
Survival Analysis
1
2019
1269
0.130
 Why?
Adolescent
5
2022
20303
0.120
 Why?
Dose-Response Relationship, Drug
2
2017
2008
0.120
 Why?
Opiate Substitution Treatment
1
2016
136
0.120
 Why?
Regulatory Sequences, Ribonucleic Acid
1
2014
19
0.120
 Why?
AIDS-Related Opportunistic Infections
1
2015
123
0.110
 Why?
Chemokines
1
2015
226
0.110
 Why?
Chemokine CXCL10
1
2014
35
0.110
 Why?
Drug Interactions
1
2015
393
0.110
 Why?
Phenylenediamines
1
2013
9
0.110
 Why?
Viral Proteins
2
2014
327
0.110
 Why?
Fibrosis
1
2016
520
0.110
 Why?
Prognosis
2
2019
3772
0.100
 Why?
Quality of Life
1
2025
2685
0.100
 Why?
Microbial Sensitivity Tests
2
2012
347
0.100
 Why?
Drug Combinations
3
2019
330
0.100
 Why?
Drug Discovery
1
2013
131
0.100
 Why?
Administration, Oral
1
2014
785
0.090
 Why?
Mental Disorders
1
2020
1028
0.090
 Why?
Cohort Studies
5
2024
5408
0.090
 Why?
Case-Control Studies
2
2017
3377
0.090
 Why?
Telemedicine
1
2020
789
0.090
 Why?
Models, Molecular
3
2012
1486
0.090
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2013
252
0.090
 Why?
Prodrugs
1
2011
48
0.090
 Why?
Nucleosides
1
2010
27
0.090
 Why?
Japan
2
2021
98
0.090
 Why?
Riboswitch
1
2012
67
0.090
 Why?
Prospective Studies
4
2023
7121
0.080
 Why?
Drug Administration Schedule
3
2017
768
0.080
 Why?
Cell Line, Tumor
2
2008
3201
0.080
 Why?
Risk Assessment
1
2019
3233
0.080
 Why?
Drug Design
1
2010
156
0.080
 Why?
Biomarkers
1
2020
3966
0.080
 Why?
Cell Line
2
2012
2779
0.080
 Why?
Piperidines
1
2010
198
0.080
 Why?
Body Mass Index
1
2017
2272
0.070
 Why?
Practice Guidelines as Topic
1
2016
1497
0.070
 Why?
Phenylthiourea
1
2008
5
0.070
 Why?
Immunity, Innate
1
2014
803
0.070
 Why?
Plasmids
1
2009
358
0.070
 Why?
Structure-Activity Relationship
1
2009
543
0.070
 Why?
Inhibitory Concentration 50
1
2006
86
0.070
 Why?
Luciferases
1
2006
147
0.070
 Why?
Genes, Reporter
1
2006
265
0.060
 Why?
Thailand
1
2025
15
0.060
 Why?
Pandemics
2
2024
1482
0.060
 Why?
Saquinavir
1
2004
1
0.060
 Why?
Simplexvirus
1
2005
80
0.060
 Why?
Indinavir
1
2004
7
0.060
 Why?
Uganda
1
2025
70
0.060
 Why?
Nelfinavir
1
2004
9
0.060
 Why?
Drug Labeling
1
2005
40
0.060
 Why?
Nevirapine
1
2004
17
0.060
 Why?
Oxazines
1
2004
27
0.060
 Why?
Benzoxazines
1
2004
30
0.060
 Why?
Lopinavir
1
2004
30
0.060
 Why?
Time Factors
1
2015
6543
0.060
 Why?
Brazil
1
2025
154
0.060
 Why?
Alkynes
1
2004
54
0.060
 Why?
Zidovudine
1
2004
78
0.060
 Why?
Pregnancy
1
2017
6391
0.060
 Why?
Liver Function Tests
1
2004
112
0.060
 Why?
South Africa
1
2025
192
0.060
 Why?
Reverse Transcriptase Inhibitors
1
2004
83
0.060
 Why?
Transfection
1
2006
915
0.060
 Why?
Carcinoma, Hepatocellular
1
2006
272
0.060
 Why?
Bone Marrow Transplantation
1
2005
275
0.060
 Why?
Pyrimidinones
1
2004
103
0.050
 Why?
Recombinant Fusion Proteins
1
2006
648
0.050
 Why?
Double-Blind Method
2
2021
1875
0.050
 Why?
Polyphosphates
1
2022
36
0.050
 Why?
Republic of Korea
1
2021
29
0.050
 Why?
Singapore
1
2021
20
0.050
 Why?
Liver Neoplasms
1
2006
640
0.050
 Why?
Retrospective Studies
5
2019
14455
0.050
 Why?
Dried Blood Spot Testing
1
2022
94
0.050
 Why?
Emergency Service, Hospital
2
2023
1896
0.050
 Why?
Mexico
1
2021
190
0.040
 Why?
Protein Biosynthesis
2
2014
405
0.040
 Why?
Raltegravir Potassium
1
2019
17
0.040
 Why?
Intensive Care Units
1
2024
736
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2019
72
0.040
 Why?
Clinical Trials, Phase III as Topic
1
2019
93
0.040
 Why?
Drug Resistance, Multiple, Viral
1
2017
11
0.030
 Why?
Longitudinal Studies
1
2024
2716
0.030
 Why?
Kinetics
1
2020
1644
0.030
 Why?
Oxygen
1
2021
915
0.030
 Why?
Medicaid
1
2020
431
0.030
 Why?
Program Evaluation
1
2020
872
0.030
 Why?
Incidence
2
2013
2636
0.030
 Why?
RNA
1
2022
880
0.030
 Why?
Cell-Free System
1
2014
48
0.030
 Why?
Hepatitis C Antibodies
1
2014
9
0.030
 Why?
Spain
1
2014
34
0.030
 Why?
Enzyme-Linked Immunosorbent Assay
1
2016
833
0.030
 Why?
Polymorphism, Genetic
1
2017
639
0.030
 Why?
Aged, 80 and over
2
2019
7055
0.030
 Why?
Patient Acceptance of Health Care
1
2020
757
0.030
 Why?
Patient Reported Outcome Measures
1
2017
372
0.030
 Why?
Risk Factors
2
2020
9745
0.030
 Why?
Patient Care
1
2014
108
0.030
 Why?
Withholding Treatment
1
2013
71
0.030
 Why?
Early Diagnosis
1
2014
233
0.030
 Why?
Plasma
1
2014
205
0.020
 Why?
Fluorescence Resonance Energy Transfer
1
2012
175
0.020
 Why?
Virus Internalization
1
2010
47
0.020
 Why?
Ligands
1
2012
621
0.020
 Why?
Pilot Projects
1
2015
1584
0.020
 Why?
Recombinant Proteins
1
2013
1304
0.020
 Why?
Magnesium
1
2009
153
0.020
 Why?
Lamivudine
1
2009
61
0.020
 Why?
Genome, Viral
1
2009
128
0.020
 Why?
Referral and Consultation
1
2014
727
0.020
 Why?
Logistic Models
1
2013
1984
0.020
 Why?
Phenotype
1
2014
3074
0.020
 Why?
Base Sequence
1
2009
2146
0.020
 Why?
Severity of Illness Index
1
2013
2737
0.020
 Why?
Randomized Controlled Trials as Topic
1
2011
1364
0.010
 Why?
Mice, Transgenic
1
2009
2117
0.010
 Why?
Animals
2
2018
35307
0.010
 Why?
Substance-Related Disorders
1
2011
1019
0.010
 Why?
Signal Transduction
1
2009
4926
0.010
 Why?
Mice
1
2009
16915
0.010
 Why?
Wyles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (239) concept(s)
_
Co-Authors Expand Description
See all (18) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)